We are a Houston-based biotech company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse age-related muscle weakness (sarcopenia), Type 2 diabetes, obesity, and muscular dystrophies.
Stan Watowich, PhD
Founder & CEO
Dr. Watowich is an inventor of Ridgeline Therapeutics' technology, upon which he founded the company. He serves as the company's CEO to help with the launch and capitalization of the company. Additionally, he is an Associate Professor of Biochemistry & Molecular Biology at the University of Texas Medical Branch and recent director of the University of Texas (UT) System's state-wide entrepreneurship program developed in partnership with UT McCombs School of Business. He is an accomplished educator, researcher, serial inventor, entrepreneur, and developer of innovative world-class resources.
Harshini Neelakantan, PhD
Exec. Director, Research & Development
Dr. Neelakantan is a co-inventor of Ridgeline Therapeutics' founding technology, an established pharmaceutical scientist with more than a decade of experience in hit-to-lead, translational in vivo validation, and preclinical therapeutics development for various disease indications, including metabolic (obesity), neurological (acute and chronic pain), neuropsychiatric (addiction sciences), and muscular diseases. Dr. Neelakantan is experienced with commercialization plan development and NIH SBIR proposal development.
Suzanne Tomlinson, PhD, MBA
Director, Finance & Operations
Dr. Tomlinson is a biochemical scientist, an entrepreneur, a leader in the development of strategic inter-institutional alliances, and a financial strategy expert. In her more than 15 years of experience in drug discovery and development she has helped develop therapies for a variety of disease indications, including colon cancer, substance use disorders, and infectious disease.
Andrea Wiley, PhD
Dr. Wiley is a translational scientist with nearly a decade of experience in non-clinical therapeutic efficacy studies which have spanned metabolic, neurological, and musculoskeletal disorders. Dr. Wiley is also a proficient data analyst, with publications using a variety of big data (i.e., proteomics, metabolomics, epigenomics, electronic health records).
Michaels Glassman, PhD
Dr. Glassman is a medicinal and computational chemist with 7+ years in the field, and expertise in retrosynthetic analysis, natural product synthesis, and reaction optimization. Dr. Glassman's leadership efforts in small molecule drug discovery research and development projects has substantially advanced multiple therapeutics.